Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Index Can Predict Survival in Patients with MM

Clin Lymphoma Myeloma Leuk; ePub 2017 Sep 19; Ely, et al

Plasma cell proliferation index (PCPI) can help predict overall survival in people with newly diagnosed multiple myeloma, according to a study involving 151 individuals. Furthermore, it enables broader use of multiple myeloma cell proliferation for categorizing risk. Investigators grouped participants based on low (n=87) and high (n=64) myeloma cell proliferation. Using a plasma cell-specific biomarker, they evaluated how well multiplex immunohistochemistry calculated a PCPI. Among the results:

  • Median overall survival was not reached in the low PCPI group, vs ~79 months in the high PCPI group.
  • Only high-risk cytogenetics, ISS stage >I, and PCPI >5 independently impacted overall survival.
  • 36% of patients with low risk disease were re-identified as high risk by PCPI.

Citation:

Ely S, Forsberg P, Ouansafi I, et al. Cellular proliferation by multiplex immunohistochemistry identifies high risk multiple myeloma in newly diagnosed, treatment naïve patients. [Published online ahead of print September 19, 2017]. Clin Lymphoma Myeloma Leuk. doi:10.1016/j.clml.2017.09.010.

This Week's Must Reads

Gene sequencing bone marrow in myelodysplastic syndrome, Duncavage EJ et al. N Engl J Med 2018;379:1028-41.

Levofloxacin prophylaxis in ALL, AML , Alexander S, et al. JAMA. 2018;320(10):995-1004

Genetic markers signal poor prognosis in MCL, Obr A et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 23. doi: 10.1016/j.clml.2018.07.282

Disparities in ALL treatment toxicity, Taylor OA et al. Clin Cancer Res. 2018 Sep 11. doi: 10.1158/1078-0432.CCR-18-0939

Leukemia risk after maternal contraception use, Hargreave M et al. Lancet Oncol. 2018 Sep 6. doi: 10.1016/S1470-2045(18)30479-0

Must Reads in Multiple Myeloma

Osteoporosis tied to mortality risk in women with multiple myeloma, Rosko AE et al. Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):597-602.e1.

Improved myeloma outcomes associated with having prescription drug coverage, Olszewski A et al. J Clin Oncol. 2018 Aug 16. doi: 10.1200/JCO.2018.77.8894

Simulated model could target myeloma treatment, Ubels J et al. Nat Commun. 2018 Jul 27. doi: 10.1038/s41467-018-05348-5.

Researchers propose frailty index for older patients with multiple myeloma, Mian HS et al. JCO Clin Cancer Inform. 2018 Jul 25. doi: 10.1200/CCI.18.00043.

Myeloma PFS boosted by elotuzumab add-on therapy, Dimopoulos MA et al. EHA (European Hematology Association) Congress, Abstract LB2606.